In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
NovoCure Ltd (NASDAQ: NVCR) closed the day trading at $19.36 down -1.17% from the previous closing price of $19.59. In other words, the price has decreased by -$1.17 from its previous closing price. On the day, 0.92 million shares were traded. NVCR stock price reached its highest trading level at $19.455 during the session, while it also had its lowest trading level at $18.88.
Ratios:
For a better understanding of NVCR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.46. In the meantime, Its Debt-to-Equity ratio is 1.90 whereas as Long-Term Debt/Eq ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on December 02, 2024, Upgraded its rating to Outperform and sets its target price to $30 from $18 previously.
On October 16, 2024, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $24 to $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 03 ’25 when Weinberg Uri sold 268 shares for $18.92 per share. The transaction valued at 5,071 led to the insider holds 166,243 shares of the business.
Leonard Frank X sold 2,527 shares of NVCR for $46,841 on Mar 03 ’25. The EVP, Pres., Novocure Oncology now owns 143,673 shares after completing the transaction at $18.54 per share. On Mar 03 ’25, another insider, Cordova Ashley, who serves as the Chief Executive Officer of the company, sold 2,053 shares for $18.54 each. As a result, the insider received 38,055 and left with 204,005 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVCR now has a Market Capitalization of 2127954432 and an Enterprise Value of 1851429760. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.52 while its Price-to-Book (P/B) ratio in mrq is 5.83. Its current Enterprise Value per Revenue stands at 3.059 whereas that against EBITDA is -11.742.
Stock Price History:
The Beta on a monthly basis for NVCR is 0.61, which has changed by 0.4203962 over the last 52 weeks, in comparison to a change of 0.07465422 over the same period for the S&P500. Over the past 52 weeks, NVCR has reached a high of $34.13, while it has fallen to a 52-week low of $11.70. The 50-Day Moving Average of the stock is -16.71%, while the 200-Day Moving Average is calculated to be -6.44%.
Shares Statistics:
Over the past 3-months, NVCR traded about 969.37K shares per day on average, while over the past 10 days, NVCR traded about 944860 shares per day. A total of 108.52M shares are outstanding, with a floating share count of 98.34M. Insiders hold about 10.53% of the company’s shares, while institutions hold 83.63% stake in the company. Shares short for NVCR as of 1740700800 were 5216483 with a Short Ratio of 5.38, compared to 1738281600 on 4971800. Therefore, it implies a Short% of Shares Outstanding of 5216483 and a Short% of Float of 5.6500003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of NovoCure Ltd (NVCR) in the stock market.The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.43 and low estimates of -$0.71.
Analysts are recommending an EPS of between -$1.7 and -$2.79 for the fiscal current year, implying an average EPS of -$2.05. EPS for the following year is -$2.0, with 7.0 analysts recommending between -$1.48 and -$2.59.
Revenue Estimates
6 analysts predict $147.57M in revenue for the current quarter. It ranges from a high estimate of $150.3M to a low estimate of $145M. As of the current estimate, NovoCure Ltd’s year-ago sales were $138.5MFor the next quarter, 6 analysts are estimating revenue of $150.53M. There is a high estimate of $152.1M for the next quarter, whereas the lowest estimate is $148M.
A total of 6 analysts have provided revenue estimates for NVCR’s current fiscal year. The highest revenue estimate was $619M, while the lowest revenue estimate was $608M, resulting in an average revenue estimate of $613.71M. In the same quarter a year ago, actual revenue was $605.22MBased on 7 analysts’ estimates, the company’s revenue will be $674.69M in the next fiscal year. The high estimate is $701.7M and the low estimate is $649M.
